Thiogenesis Therapeutics, Corp. Announces Closing of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - April 5, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that on March 31, 2022, it closed its previously announced Qualifying Transaction (the "QT") as defined by Policy 2.4 of the TSX Venture Exchange (the "Exchange") with Thiogenesis Therapeutics, Inc. ("TTI-US") (see the Company's press releases dated March 12, 2021, March 23, 2021, July 27, 2021 and March 21,...
2022-04-05 4:57 PM EDT
Rozdil Capital Corporation Completes Initial Public Offering; Common Shares Commence Trading
Toronto, Ontario--(Newsfile Corp. - July 16, 2019) - Rozdil Capital Corporation (TSXV: ROZ.P) (the "Corporation") is pleased to announce that it has successfully completed its initial public offering of 2,150,000 common shares (the "Common Shares") at $0.10 per share for gross proceeds of $215,000 (the "Offering"). As a result of this issuance, the Corporation has 4,500,000 Common Shares issued and outstanding, of which 2,350,000 Common Shares are subject to escrow restrictions as disclosed...
2019-07-16 9:00 AM EDT